For full functionality, including active links, we recommend downloading the PDF. Certain interactive features may not operate within the embedded viewer.
Download this PDF file

 

Crossref Citations

1. Adequacy of recommendations for adverse event management in national and international treatment guidelines for rifampicin-susceptible tuberculosis: a systematic review
William Burman, Jayne Ellis, Gila Hale, Katherine Hill
eClinicalMedicine  vol: 82  first page: 103148  year: 2025  
doi: 10.1016/j.eclinm.2025.103148

2. Molecular links between tuberculosis and lung cancer: pathogenesis and therapeutic challenges
Francis Adu-Amankwaah, Suzzana Dickson Buabeng, Isabella Sanette Agyekum, Ndivhuwo Tshililo, Lucinda Baatjies, Bienyameen Baker
Archives of Microbiology  vol: 208  issue: 1  year: 2026  
doi: 10.1007/s00203-025-04592-w

3. Risk factors for drug-induced liver injury in people with HIV on anti-tuberculosis treatment
Pedro Martínez-Ayala, Moises Salgado-de la Mora, José Antonio Velarde-Ruiz Velasco, Luz Alicia González-Hernández, Fernando Amador-Lara, Guillermo Adrián Alanis-Sánchez, Juan Manuel Aldana-Ledesma, Christian Gerardo Alfaro-Rivera, Sergio Zúñiga-Quiñonez, Vida Verónica Ruiz-Herrera, Paulina Alejandra Sánchez-Álvarez, Jaime Federico Andrade-Villanueva
Enfermedades infecciosas y microbiologia clinica (English ed.)  vol: 44  issue: 5  first page: 503041  year: 2026  
doi: 10.1016/j.eimce.2026.503041

4. Multi‐Targeted Hepatoprotection: A Combined Extract of Moringa oleifera and Urtica dioica (MU) Combats Drug‐Induced Oxidative Stress and Inflammation via Antioxidant and Molecular Modulatory Effects
Nassima Boutaoui, Nesrine Lariche, Mohamed Zakaria Stiti, Katia Mohand Saidi, Walid Bousbaa, Khellaf Rebbas, Kamel Harrouche, Smail Khelili
Chemistry & Biodiversity  vol: 23  issue: 4  year: 2026  
doi: 10.1002/cbdv.202502542

5. Genetic polymorphisms and adverse reactions to antituberculosis therapy
Hannah M Gunter, Phuti Choshi, Tafadzwa Chimbetete, Sarah Pedretti, Rannakoe J Lehloenya, Phumla Z Sinxadi, Marylyn D Ritchie, Elizabeth J Phillips, David W Haas, Jonny G Peter
Pharmacogenomics  vol: 26  issue: 5-6  first page: 207  year: 2025  
doi: 10.1080/14622416.2025.2509479

6. Risk factors associated with anti-tubercular therapy-induced hepatitis in human immunodeficiency virus seropositive and seronegative patients in India
Aneez Jamal KM, Ashutosh Bhosale, Muralidhar Varma, Rajesh Radhakrishnan
International Journal of Risk & Safety in Medicine  vol: 37  issue: 1  first page: 131  year: 2026  
doi: 10.1177/09246479251401359

7. Risk factors for drug-induced liver injury in people with HIV on anti-tuberculosis treatment
Pedro Martínez-Ayala, Moises Salgado-de la Mora, José Antonio Velarde-Ruiz Velasco, Luz Alicia González-Hernández, Fernando Amador-Lara, Guillermo Adrián Alanis-Sánchez, Juan Manuel Aldana-Ledesma, Christian Gerardo Alfaro-Rivera, Sergio Zúñiga-Quiñonez, Vida Verónica Ruiz-Herrera, Paulina Alejandra Sánchez-Álvarez, Jaime Federico Andrade-Villanueva
Enfermedades Infecciosas y Microbiología Clínica  vol: 44  issue: 5  first page: 503041  year: 2026  
doi: 10.1016/j.eimc.2025.503041

8. Host Serum Biomarker Signatures in Mycobacteriologically Cured Pulmonary Tuberculosis Patients with Persistent Lung Inflammation on 18F-FDG PET/CT
Bongani Motaung, Solima Sabeel, Mumin Ozturk, Trevor S. Mafu, Muki Shey, Sandra L. Mukasa, Karen Wolmarans, Fareda Jakoet-Bassier, Ashleigh Taylor, Antoneta Mashinyira, Tessa Kotze, Friedrich Thienemann, Reto Guler
Diseases  vol: 14  issue: 2  first page: 70  year: 2026  
doi: 10.3390/diseases14020070